Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 7/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | LIG1 | P18858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3074364 | 1.00 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL70493 | 0.97 | DAO (0.67) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL27562112 | 0.94 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL28353716 | 0.94 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL11598753 | 0.94 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL29808747 | 0.94 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL19987844 | 0.94 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL28343181 | 0.94 | DAO (0.64) | DAOPKMLIG1MEN1POLB | |
| SCHEMBL28064033 | 0.91 | DAO (0.61) | DAOPKMLIG1MEN1POLB | |
| Ethylene SCHEMBL28343669 | 0.91 | DAO (0.61) | DAOPKMLIG1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108863823-B | Diphenol monomer containing asymmetric fluorophore structure and preparation method and application thereof | 吉林大学 | 2020-02-07 | — | — | CN | disclosed |
| EP-2543661-B1 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING BV (NL) | 2016-12-07 | — | — | EP | disclosed |
| EP-1778265-B1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | FERRING BV (NL) | 2013-04-24 | — | — | EP | disclosed |
| EP-2543661-A1 | Guanylhydrazone compounds, compositions, methods of making and using | Cytokine Pharmasciences, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-8247455-B2 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING B.V. (NL) | 2012-08-21 | — | — | US | disclosed |
| US-20110144189-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7863334-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-7291647-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060041002-A1 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING BV (NL) | 2006-02-23 | — | — | US | disclosed |
| EP-0795765-B1 | Photopolymerizable composition and transparent cured product thereof | TOKUYAMA CORP (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-5880170-A | TRANSPARENT LENSES FORMED BY CURING | TOKUYAMA CORPORATION (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0795765-A2 | Photopolymerizable composition and transparent cured product thereof | TOKUYAMA CORPORATION (JP) | 1997-09-17 | — | — | EP | disclosed |
| US-5233017-A | Nonlinear optical materials | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1993-08-03 | — | — | US | disclosed |
| US-4581445-A | DYEING PAPER | CIBA-GEIGY CORPORATION (US) | 1986-04-08 | — | — | US | disclosed |
| US-4093622-A | Pyridine esters of cyclopropane-carboxylic acid | ZOECON CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | GMPS, GANC, GLO1 | GAA 344/4885DAO 568/4885PKM 1446/4885 |
| US-20110144189-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | GMPS, GANC, GLO1 | GAA 344/4885DAO 568/4885PKM 1446/4885 |
| US-20060041002-A1 | Guanylhydrazone compounds, compositions, methods of making and using | GMPS, GANC, GLO1 | GAA 344/4885DAO 568/4885PKM 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.